Tomáš V.
- Country
- Czechia
- Department
- Plicní oddělení
Research Overview
- A Phase III, Multicentre, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations (Oberon)
- A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (PROSPERO)
Data & Insights
Has run more than one trial at 55 of 139 partner sites.
Specializations
Cardiovascular disease
Clinical research is centered on acute myocardial infarction, acute coronary syndrome, heart failure, and prevention of recurrent cardiovascular events. The portfolio also includes interest in stroke prevention, atrial fibrillation, and atherosclerotic cardiovascular disease.
- Myocardial infarction and ischemic heart disease
- Heart failure and acute decompensation
- Stroke prevention and thromboembolic risk
- Lipid-lowering and cardiometabolic risk
The therapeutic focus extends to early intervention in ST-elevation and non-ST-elevation myocardial infarction, with additional involvement in treatments aimed at reducing residual inflammatory and thrombotic risk.
Pulmonary and respiratory medicine
Research activity reflects a strong commitment to chronic obstructive pulmonary disease, acute respiratory distress syndrome, and advanced lung cancer. The investigator is involved in studies addressing both inflammatory lung disease and malignant thoracic disease.
- COPD and exacerbation prevention
- ARDS related to pneumonia or infection
- Non-small cell lung cancer
- Small cell lung cancer
Therapeutic interests include respiratory support in severe inflammatory lung injury and systemic treatment strategies for advanced thoracic malignancies.
Hepatology and metabolic liver disease
The clinical landscape includes non-alcoholic steatohepatitis, metabolic dysfunction-associated steatotic liver disease, primary biliary cholangitis, chronic hepatitis D, and cirrhosis. This area also covers liver injury linked to alcohol-related disease and inflammatory liver disorders.
- NASH and fibrosis
- MASLD and metabolic liver dysfunction
- Primary biliary cholangitis
- Chronic hepatitis D infection
Investigational interest is directed toward therapies that target liver inflammation, fibrosis progression, and preservation of hepatic function in chronic liver disease.
Genitourinary oncology
Oncology involvement is notable in prostate cancer and bladder cancer, including metastatic castration-resistant prostate cancer, metastatic hormone-sensitive prostate cancer, and high-risk non-muscle-invasive bladder cancer. The portfolio also includes advanced breast cancer.
- Prostate cancer across localized and metastatic settings
- Non-muscle-invasive bladder cancer
- Advanced breast cancer
- Hormone receptor-positive and HER2-negative disease
Therapeutic interest centers on disease control in hormonally driven malignancies and bladder cancer recurrence prevention.
Infectious disease, hematology, and other internal medicine areas
Additional research activity includes Clostridioides difficile infection, complicated urinary tract infection, acute pyelonephritis, and hemophilia A and B. The investigator is also involved in studies of chronic pain and selected rare or systemic conditions.
- Antimicrobial therapy for urinary and gastrointestinal infection
- Hemophilia and joint health
- Chronic non-specific low back pain
- Rare systemic disorders
These areas show interest in infection management, bleeding disorders, and symptom-focused treatment options in chronic internal medicine.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.